TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00230113

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid diet supplementation
Description: 4 gm fish oil per day
Study: NCT03420872

Intervention type: OTHER
Intervention: Nutrient mixtures
Description: consumption of a mixture of beneficial nutrients
Study: NCT02412098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Eleclazine tablets administered orally
Study: NCT05647590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 3 months of platinum doublet chemotherapy (cDDP / CBDCA + Pemetrexed, NVB)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) + Stereotactic Body Ratio Therapy (SBRT)
Description: * RT to primary tumor + SBRT to all oligometa (max. 10 intra / extracranial lesions, intracranial SD / PR)~* SBRT V \< 100 ml, if technically possible fractionation RT (40 - 50 Gy / 16 - 20 fractions), SBRT (30 Gy / 1 fraction, 50 - 60 Gy / 3 - 5 fractions) 3 - 6 weeks ... maintenance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Description: Maintenance chemotherapy will follow 3-6 weeks after RT.
Study: NCT00930085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SELDI-TOF MS for plasmatic proteic profile
Description: An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
Study: NCT04014283

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium supplementation or placebo treatment
Description: Patients from this group will receive selenium supplement to achieve optimal selenium level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet modification
Description: Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet modification
Description: Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet modification
Description: Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selenium supplementation or placebo treatment and diet modification
Description: In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
Study: NCT00295542

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy, timing of antihypertensive medication
Description: Comparison of effects of awakening versus bedtime dosing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chronotherapy, timing of antihypertensive medication
Description: Comparison of effects of awakening versus bedtime dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI (including spirapril, enalapril, quinapril, lisinopril)
Description: Treatment at awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEI (including spirapril, enalapril, quinapril, lisinopril)
Description: Treatment at awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARB (including valsartan, telmisartan, olmesartan)
Description: Treatment at awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARB (including valsartan, telmisartan, olmesartan)
Description: Treatment at awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers (including nebivolol, atenolol, carvedilol)
Description: Treatment at awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta blockers (including nebivolol, atenolol, carvedilol)
Description: Treatment at awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diuretics (torasemide, indapamide, HTCZ) and doxazosin
Description: Treatment at awakening versus bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diuretics (torasemide, indapamide, HTCZ) and doxazosin
Description: Treatment at awakening versus bedtime

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy in essential hypertension
Description: Treatment at awakening versus bedtime

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combination therapy in essential hypertension
Description: Treatment at awakening versus bedtime
Study: NCT02151669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
Study: NCT02286921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
Study: NCT04170543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Dose 1, Dose 2, Dose 3, Dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Dose 1, Dose 2, Dose 3, Dose 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Dose 1, Dose 2, Dose 3, Dose 4
Study: NCT03937362

Intervention type: DIAGNOSTIC_TEST
Intervention: First clinical response evaluation (CRE-1)
Description: Consisting of: endoscopy with bite-on-bite biopsies

Intervention type: DIAGNOSTIC_TEST
Intervention: Second clinical response evaluation (CRE-2)
Description: Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA
Study: NCT05716308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A continuous nursing intervention group was established.
Description: Intervention group: Continuous nursing intervention was performed on the basis of the control group: ①A continuous nursing intervention group was established. The group members included chief physician, attending physician, head nurse, specialist nurse and nutritionist. ②The establishment of patient records, patients admitted to hospital by the primary nurse to record the basic situation of patients, including name, age, history of diabetes, DR staging, vision and blood glucose before treatment and other information. ③Personalized nursing intervention was given during hospitalization. Systematic health education was carried out for patients on admission. Targeted psychological counseling was given to some patients. ④After discharge to give continuous care, organize patients to join the WeChat group, group to share knowledge of DR-related diseases, to understand the patient 's medication, diet, vision, the patient 's questions and problems to guide and improve.
Study: NCT03161652

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DME plus ranibizumab lactose pill
Description: Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DME plus ranibizumab levosulpiride
Description: Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
Study: NCT02016534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: AMG 337 300mg orally daily.
Study: NCT02162056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of bioresorbable vascular scaffolds
Description: Implantation of bioresorbable vascular scaffolds for coronary artery disease.
Study: NCT03817125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for antibiotic
Description: Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin pretreatment
Description: Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
Study: NCT00230113

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: safflower oil
Description: 4 gm per day safflower oil
Study: NCT00187174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The drug is given orally in 28 day courses.
Study: NCT03817125

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for SER-401
Description: Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-401
Description: Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
Study: NCT03879785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Screening and validation of assessment tool translated into Spanish

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Screening and validation of assessment tool translated into Spanish
Study: NCT00927589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Intravenous repeating dose
Study: NCT00596531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: Oral administration, 666 mg, tid, for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of 2 pills, tid, for 4 months
Study: NCT04823065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide Pill
Description: 4 mg Imodium, per os

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine-n-butylbromide
Description: 3 X 20 mg Buscopan, intravenous
Study: NCT03807570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Morus Alba L. Extract
Description: Morus Alba L. Extract 30 ml/day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 ml/day for 12 weeks.
Study: NCT01545648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection
Study: NCT01224405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel + LH-RH analogues
Description: Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced \>50%. Docetaxel treatment will be resumed when the serum PSA will rise by \>50% from the lowest PSA level recorded and will be \>10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Docetaxel
Description: Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Docetaxel
Description: Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced \>50% or will reach a level \<4 ng/mL.
Study: NCT01651117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Patients will receive peer mentoring.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Patients will receive peer mentoring.
Study: NCT04382729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: The intervention group, in addition to the daily routine physical therapy, receives NMES for 15 days (5 days per week for 3 weeks). NMES is applied bilaterally using an electrical stimulator with pairs of electrodes placed transversally on the quadriceps muscles and on the gastrocnemius muscles. The stimulation protocol consists in the application of symmetrical biphasic rectangular pulses with a frequency of 30 Hz (pulse duration: 400 µs). Stimulation intensity is adjusted daily by the physical therapist to elicit a visible twitch in each muscle. The total duration of the NMES session is 30 min for the first week and 45 min for the second and third week. Stimulation (on) time is 5 s and relaxation (off) time is 15 s, thus eliciting a total of 90 evoked contractions per day during the first week and 135 contractions per day during the second and third week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy Exercise
Description: The control group is subjected to a protocol of physical therapy exercises, applied once a day for 30 minutes (5 days per week for 3 weeks) by the staff physical therapists. It starts with global passive range of motion exercises, followed by active and resistive exercises (including controlled breathing exercises and respiratory muscle training), transfer to the edge of the bed or to a chair, standing and walking.
Study: NCT02832232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: translational dorsal glide mobilization technique grade III
Description: Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure maintained suboccipital Inhibition technique
Description: Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
Study: NCT06160609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin
Description: Belantamab Mafodotin will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3174998
Description: GSK3174998 will be administered.
Study: NCT02251483

Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00287586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel (Androgel)
Description: 7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching testosterone gel daily for 3 years
Study: NCT01547429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artisan Aphakia Intraocular Lens
Description: Implantation of lens to correct refractive error in aphakic eye
Study: NCT00537173

Intervention type: PROCEDURE
Intervention: Core Biopsy
Description: biopsy

Intervention type: PROCEDURE
Intervention: Blood Collection
Description: Blood/serum sample

Intervention type: DRUG
Intervention: Paclitaxel
Description: Paclitaxel 90 mg/m2 IV, day 1, 8 and 15

Intervention type: DRUG
Intervention: Avastin
Description: Avastin 10 mg/kg IV, day 1 and 15
Study: NCT02526667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: 2% CHG solution on cloth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DynaHex-2
Description: 2% CHG solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Excipients of CHG product only
Study: NCT01607450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 Low Dose
Description: 0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 Mid-Range Dose
Description: 1.5mmol/kg/min for 12 hours prior to PET study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 High Dose
Description: 4.0mmol/kg/min GLP-1 for 12 hours prior to PET study

Intervention type: DRUG
Group type: OTHER
Intervention: Saline
Description: Normal saline placebo infusion for 12 hours prior to PET study
Study: NCT03274193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga training program
Description: The hatha yoga program will be led by an experienced yoga instructor. Each 60 minutes session will consist of 10 minutes of breathing exercises (pranayama), 40 minutes of yoga pose practice (asana), and 10 minutes of supine meditation/relaxation (savasana). Yoga props, such as blocks and belts, will be used in accordance to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably. The yoga poses are chosen for providing a restorative session and based on their purported relationship to restorative effects. Participants will be instructed to maintain their concentration and breath control at all times during the yoga session.
Study: NCT04055740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS Imaging
Description: IVUS or radial-ICE (intracardiac echocardiography) is a visualization tool used in many cardiac procedures including electrophysiology procedures (catheter ablation). Its utility in identifying ILA will be assessed in this study.